The small cap biotech Instil Bio tries to follow in Summit’s slipstream.

Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.

It’s back to school for biotech, with a packed conference schedule.

The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.

As the dust settles on ASCO the weekend’s immediate winners and losers emerge.

The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.

Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.

The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.